الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Aim of the work
To use high dose intravenous immunoglobulin beside the conventional treatment measures of neonatal immune hemolytic jaundice aiming at reducing the haemolysis, serum bilirubin levels, the need for blood exchange transfusions and the duration of hospital stay at the neonatal intensive care units.
Conclusion
From following up the progress of the treatment and the control groups, it was noticed that:
1- The duration of phototherapy and hence the duration of hospital stay was significantly lower in the treatment group than that in the control group.
2- The number of exchange transfusions needed was significantly lower in the treatment group than that needed for the control group.
3- There was no significant difference in the response to the use of high dose intravenous immunoglobulin therapy regarding the type of incompatibility (ABO, Rh or ABO with Rh incompatibility) i.e. the three types of incompatibility responded well to the high dose intravenous immunoglobulin therapy.
4- No side effects of high dose intravenous immunoglobulin therapy were observed except a late anemia (after 2-3 weeks of the therapy) which was mild and occurs in a low percentage of newborns who received the HDIVIG therapy (about 6.6% of treatment group). This anemia was corrected by a single blood transfusion and no other delayed adverse effects were observed.
From this study it may be concluded that high dose intravenous immunoglobulin therapy in newborns with ABO or Rh hemolytic disease reduces the hemolysis, serum bilirubin levels and the need for blood exchange transfusion, a procedure which has potential complications and carries a risk of mortality.